Bio-tech startup Venomics AI raises $2.7 M Pre-seed funding

Venomics AI, a biotechnology startup spun out of the Indian Institute of Science (IISc), has raised $2.7 million in its maiden institutional funding round. The pre-seed round was jointly led by Speciale Invest and South Park Commons, with additional participation from Operators Studio.
The company will deploy the funds to expand its operations, enlarge its molecular dataset and enhance its artificial intelligence and laboratory screening capabilities, Venomics AI said in a press release.
Founded in May 2026 by Sunagar and Vinay Prabhu, Venomics AI brings together venom biology, molecular sequencing, AI and experimental screening to identify and develop potential therapeutics derived from venom.
Headquartered in Bengaluru, the startup is developing Venom Atlas, a platform that integrates molecular data obtained from venom with laboratory validation and drug discovery processes. The platform uses AI to identify and rank promising molecular candidates, which are subsequently tested through functional laboratory screening. The findings from these experiments are then incorporated into further predictions and molecular design.
Venomics AI aims to leverage India’s venom biodiversity, alongside its scientific and computational capabilities, to create a drug discovery platform for developing therapeutics for global markets.
The company has already established the initial architecture of its platform, secured a place in the NVIDIA Inception programme and been named among the top five finalists for the 2026 Indo-Boston Biotech Bridge Award.
It plans to expand its multidisciplinary workforce across venom biology, computational science and drug discovery, while advancing the validation and optimisation of promising molecules.
Companies operating in this field are investigating bioactive peptides and proteins present in the venoms of snakes, scorpions and marine animals to identify compounds that could have applications in pain management, neurological disorders, cardiovascular diseases and other therapeutic areas.
Another company working in this segment is Snaayu Lifesciences, which is incubated at C-CAMP and focuses on isolating and characterising novel pain-relieving compounds derived from cone snail venom.
The wider AI-powered drug discovery sector has also drawn investor attention. Bengaluru-based Peptris Technologies secured Rs 70 crore in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest in February 2026. The startup uses AI-based molecular discovery and experimental validation to develop potential drug candidates.




